<DOC>
	<DOCNO>NCT02659215</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy Hyalofast® scaffold bone marrow aspirate concentrate ( BMAC ) compare microfracture treatment symptomatic cartilage defect knee .</brief_summary>
	<brief_title>HyaloFAST Trial Repair Articular Cartilage Knee</brief_title>
	<detailed_description>- Prospective , randomize , active treatment-controlled , evaluator-blinded ( radiologist reviewer physician evaluator ) multicenter study ( 40 site US EU ) . - All subject meet preoperative screening eligibility criterion randomize treatment Hyalofast® BMAC Microfracture . - Hyalofast® sterile , biodegradable non-woven pad ( 2 x 2 cm 5 x 5 cm ) compose HYAFF-11® , benzyl ester hyaluronic acid . Hyalofast® act biodegradable support autologous bone marrow aspirate concentrate . Hyalofast® soft conformable easily cut fit lesion size . - Autologous bone marrow harvest subject intraoperatively Index Procedure . Approximately 60 mL bone marrow aspirate subject 's iliac crest use SmartPrep 2 Bone Marrow Processing Pack . The cellular rich portion concentrate via SmartPrep BMAC 2 Centrifuge System point-of-care provide 7 mL bone marrow aspirate concentrate ( BMAC ) . 1 - 2 mLs use post-procedure test total nucleated cell , cell viability , sterility . - Hyalofast® BMAC implant either standard knee arthroscopy min-arthrotomy depend upon surgeon preference intra-operative finding . The lesion treat debrided stable cartilage margin . The defect size Hyalofast® cut fit lesion area . If necessary , one Hyalofast® pad overlap cover lesion . 2 mL BMAC load per Hyalofast® scaffold implant cover defect . Hyalofast® BMAC readily adhere site application , , necessary , secure defect margin FDA-approved fibrin glue . - All subject assess interval post-procedure ( 1 month , 3 month , 6 month , 12 month , 24 month , 36 month ) . - Subjects require follow strict pre-specified post-surgery rehabilitation protocol specific defect location . - Measures assess effectiveness conduct follow-up , primary effectiveness endpoint assessment do 24 month timepoint . - Evaluators efficacy assessment subject administer subject-reported outcome instrument blind treatment . - Safety assess collection adverse event timepoints . - Magnetic Resonance Imaging ( MRI ) conduct Screening , 1 month , 12 month , 24 month , 36 month . Evaluation MRIs , include MOCART score , do blind radiologist reviewer . The one month MRI use baseline MRI evaluation treatment effectiveness .</detailed_description>
	<mesh_term>Cartilage Diseases</mesh_term>
	<criteria>1 . Patient male female , 18 60 year age 2 . Patient 's body mass index ( BMI ) &lt; 35 kg/m2 3 . Patient symptomatic lesion femoral condyle ( medial and/or lateral ) femoral trochlea 16 cm2 screening image confirm independent radiologist 4 . The symptomatic lesion classify International Cartilage Repair Society ( ICRS ) grade 3 4 5 . Patient agree actively participate strict rehabilitation protocol followup program 6 . Patient use nonsteroidal antiinflammatory drug acetaminophen/paracetamol month signing informed consent form treat knee pain 7 . Patient willing able provide inform consent comply study requirement 8 . Patient , woman childbearing potential , must negative pregnancy test Screening , lactate willing use adequate contraception first 12 month study last surgery 9 . Patient ability consistently rate knee pain function demonstrate completion total KOOS score 10 . Patient minimum 45 100 Visual Analogue Scale ( VAS ) score index knee pain remember index knee pain medication active 11 . Patient willing use pain medication rather Nonsteroidal Antiinflammatory Drugs ( NSAIDS ) 6 month postsurgery ( e.g . acetaminophen , narcotic analgesic , prescribe ) . Postsurgical use aspirin clot prevention acceptable . 12 . Patient willing restrict pain medication 6 month postsurgery NSAIDs acetaminophen/paracetamol end trial 13 . Patient must Hematocrit ≥ 28.0 % ; White Blood Cell count ≤ 14,000 ; Platelet Count ≥ 50,000 ; Creatinine ≤ 2.0 mg/dL ; International Normalized Ratio ( INR ) ≤ 1.6 1 . Major concomitant cartilage lesion require extensive surgical treatment . ( Lesions minor loose body , small debris fragment , small cartilage fragment prominent knee fat pad allow . These lesion may treat debridement ) . 2 . Presence kiss bipolar lesion appose index lesion deeper Grade 2 ( ICRS classification ) determine MRI . ( Presence kissing ( bipolar ) lesion appose index lesion deeper Grade 2 discover arthroscopy allow ) . The nonindex lesion , indicate treatment , treat study assign treatment index lesion . 3 . Diagnosed advanced osteoarthritis demonstrate KellgrenLawrence grade 3 4 index knee 4 . Complex ligamentous instability index contralateral knee . ( Previous reconstruction Anterior Cruciate Ligament ( ACL ) Posterior Cruciate Ligament ( PCL ) allow , either index contralateral knee , instability present . Grade 1 ligamentous injury allow ) 5 . Infections skin disease target knee joint 6 . Osteochondritis dissecans ( OCD ) 7 . Patients require meniscal arrow meniscal suture 8 . Previous meniscal transplant index knee 9 . Patients previous total functional meniscectomy . ( Patients previous partial meniscectomy meniscus consider biomechanically functional allow ) 10 . Varus valgus malalignment exceed 10° either knee 11 . Patient require concomitant surgical procedure time Index Procedure osteotomy ( e.g . high tibial valgus and/or patellar realignment osteotomy ) , bone subchondral perforation , ligament surgery , meniscal surgery etc . 12 . Previous cartilage repair procedure ( microfracture , Osteochondral autograft transplantation system ( OATS ) Autologous Chondrocyte Implantation ( ACI ) without use scaffold ( matrix ) index knee 13 . Previous fail microfracture procedure index knee . ( Previous history microfracture contralateral knee allow ) 14 . Known hypersensitivity ( allergy ) hyaluronate 15 . Contraindication ( ) microfracture surgery 16 . Hyaluronic acid intraarticular injection index knee within last 90 day sign informed consent 17 . Corticosteroid therapy systemic intraarticular route within last 60 day inform consent intramuscular oral corticosteroid within last 30 day inform consent . 18 . Uncontrolled diabetes 19 . Any concomitant painful disable disease spine , hip , low limb , include contralateral knee , would interfere evaluation index knee 20 . Any clinically significant symptomatic vascular neurologic disorder low extremities 21 . Any evidence follow disease index knee : septic arthritis ; inflammatory joint disease ; gout ; recurrent episodes pseudogout ; Paget disease bone ; ochronosis ; acromegaly ; hemochromatosis ; Wilson disease ; primary osteochondromatosis ; heritable disorder ; collagen gene mutation 22 . Rheumatoid arthritis gouty arthritis 23 . Current diagnosis osteomyelitis 24 . Any result screen blood work ( include complete blood count , Prothrombin Time ( PT ) /Partial Thromboplastin Time ( PTT ) /INR , liver function , creatinine ) exceed 1.5x upper limit normal 0.5x low limit normal . 25 . Diagnosed musculoskeletal cancer diagnose cancer , musculoskeletal long term remission ( e.g . least 5 year negative biopsy last exam ) , except basal cell carcinoma 26 . Alcohol drug ( include medication ) abuse 27 . Patients high risk postsurgical bleeding ( e.g. , bleed disorder ; take anticoagulant except low dose aspirin ) postsurgical infection ( e.g. , take immunosuppressant ; severe infection history serious infection ) 28 . Contraindications MR image 29 . Patient currently receive workman 's compensation disability litigation workman 's compensation disability claim 30 . Participation concurrent trial previous trial within 90 day sign informed consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hyaluronic Acid</keyword>
	<keyword>Cartilage Repair</keyword>
	<keyword>Knee</keyword>
</DOC>